Skip to main content
. 2013 May 16;13:239. doi: 10.1186/1471-2407-13-239

Figure 2.

Figure 2

Kaplan-Meier progression-free survival and overall survival curves. a. The median progression free survival (PFS) in toremifene 120 mg/day (TOR120) was 7.3 months and that in exemestane 25 mg/day (EXE) was 3.7 months, which showed a statistically significant difference with a hazard ratio of 0.61 (95% Confidence Interval; 0.38-0.99, P = 0.045). b. Kaplan-Meier overall survival (OS) curves in the TOR120 and EXE. The median OS in TOR120 was 32.3 months and that in EXE was 21.9 months, which showed no statistical difference with a hazard ratio of 0.60 (95% CI; 0.26-1.39, P = 0.22) by log-rank test.